WO2025077711 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP)

National phase entry:
Publication Number WO/2025/077711
Publication Date 17.04.2025
International Application No. PCT/CN2024/123536
International Filing Date 09.10.2024
Title **
[English] COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP)
[French] COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE LA PROTÉINE PRÉCURSEUR DE L'AMYLOÏDE (APP)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/123698   10.10.2023   CN
PCT/CN2023/136289   05.12.2023   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting4563
EPO Filing, Examination, Granting66403
Japan Filing, Examination, Granting4036
South Korea Filing, Examination, Granting6205
USA Filing, Examination, Granting22240
MasterCard Visa
Total: 103,447

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Compositions and methods useful to reduce expression of amyloid precursor protein (APP) gene and for treatment of APP-associated diseases and conditions are provided. Provided are APP dsRNA agents, APP antisense polynucleotide agents, compositions comprising APP dsRNA agents, and compositions comprising APP antisense polynucleotide agents that can be used to reduce APP expression in cells and subjects.[French] L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène de la protéine précurseur de l'amyloïde (APP) et pour le traitement de maladies et d'états associés à l'APP. L'invention concerne des agents d'ARNdb APP, des agents polynucléotidiques antisens APP, des compositions comprenant des agents ARNdb APP, et des compositions comprenant des agents polynucléotidiques antisens APP qui peuvent être utilisés pour réduire l'expression de l'APP dans des cellules et des sujets.